Seeking adults with liver cancer for research study
Have you been diagnosed with liver cancer?
IQVIA, a global healthcare research company, is looking for people with liver cancer to participate in a telephone research study. They want to understand how people with liver cancer feel in terms of symptoms, and impact on quality of life. Qualified study participants will receive a $150 gift card.
Click to learn more and see if you qualify http://bit.ly/2sC8vpVWeb.
Download flyer here: Liver Cancer Research Study
Dr. Ghassan Abou-Alfa wins the 2018 Blue Faery Award
Dr. Ghassan Abou-Alfa from Memorial Sloan-Kettering Cancer Center specializes in the treatment of liver cancer. Dr. Abou-Alfa serves as the chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers, the chair of the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force and is the President-Elect for the International Society of Gastrointestinal Oncology. Dr. Abou-Alfa has lectured worldwide on the subject on liver cancer. He serves as the chair of the medical/scientific boards of Blue Faery and the Cholangiocarcinoma Foundation, and also serves on the National Medical Advisory Committee of the American Liver Foundation.
Seeking Adults With Primary Liver Cancer
Seeking Adults With Primary Liver Cancer (Hepatocellular Carcinoma)
If you are an adult diagnosed with primary liver cancer (i.e., Hepatocellular Carcinoma), you may qualify for a research study. You will be paid up to $175 for your participation in an individual telephone interview.
If you would like to participate in this research project, please contact Loretta at (919) 307-5762 or email@example.com
President Andrea Wilson Meets Professor Pierce Chow
At a press event, President Andrea Wilson discussed the merits of the SIRveNIB study with Professor Pierce Chow. Sponsored by Singapore General Hospital in collaboration with Singapore’s National Cancer Centre, National Medical Research Council, Clinical Research Institute and Sirtex Medical, SIRveNIB was a Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma. While the study did not meet its primary endpoint of Overall Survival, Professor Chow indicated patients suffered fewer side effects with SIRT than sorafenib.
Dr. Amit Singal wins the 2017 Blue Faery Award
Dr. Amit Singal wins the 2017 Blue Faery Award for Excellence in Liver Cancer Research
Dr. Singal is an expert in Hepatocellular Carcinoma, particularly in early tumor detection and screening process failures. He serves as Clinical Chief of Hepatology and Medical Director of the Liver Tumor Program at UT Southwestern Medical Center. Dr. Singal is leading several federal and state-funded projects to evaluate interventions to improve the effectiveness of early tumor detection efforts among patients with cirrhosis. He has published several book chapters on HCC and over 100 peer-reviewed publications.
Blue Faery exhibits at The Liver Meeting
President Andrea Wilson and Volunteer Elizabeth Marquez attended AASLD’s annual Liver Meeting in Boston from November 11 – 15. Blue Faery was one of many booths in ‘Nonprofit Row’ just outside the Exhibition Hall. With lots of foot traffic and liver cancer specialists at the meeting, Blue Faery’s HCC Patient Education brochures were a big hit along with our Blue Faery water bottles and Sharpies. Andrea attended a few oral sessions, but she spent most of her time with Elizabeth at the booth, meeting doctors from around the world who are trying to prevent, treat and cure liver cancer and other liver diseases. Andrea and Elizabeth are pictured here with Dr. Mohammad Ghauri from Pakistan.
Due to overwhelming demand at the Liver Meeting, Blue Faery’s website now translates into Urdu, the most common language spoken in Pakistan.
Join the first international survey of people living with HCC
But you are also one among tens of thousands of people like yourself, who are fighting a similar battle every day, in every country of the world. In fact, HCC is the fourth most common cancer diagnosed each year and according to the WHO, the second most common cause of cancer deaths worldwide.
Blue Faery has recently joined a special partnership of similar organizations across North America, Asia and Europe in an effort to ask hundreds of men and women like you to share your experiences by responding to the first international survey of people living with HCC. Our hope is the results of this survey will provide doctors and cancer researchers with some of the insights they need to improve liver cancer treatments. Additionally, by sharing your story, we hope to destigmatize the diagnosis of liver cancer.
The survey is online and you can access it from your personal computer at www.hcc-voices.com/us1. Your personal information and opinions will not be shared with anyone. The survey will take approximately 15 – 30 minutes, and it will be available on the web until December 31, 2016.
In addition to Blue Faery, a number of other liver cancer groups are taking part in the survey including the American Liver Foundation, British Liver Trust, Canadian Liver Foundation, European Liver Patients’ Association, Taiwan Liver Cancer Association and a number of liver cancer treatment units in major medical centers around the world. The survey was developed for these organizations by the research company, Strategic Sight, which will analyze the results in collaboration with the Medical Technology Research Group of the London School of Economics, with an unrestricted educational grant from Sirtex.
The results of the survey will be made available early in 2017, in the form of a report from the London School of Economics and the participating liver cancer groups. The survey findings will be made available to liver research organizations, scientific journals and the media.
President Andrea Wilson becomes a Focus on Research Scholar
President Andrea Wilson was accepted into the Focus on Research Scholar program, a division of the Research Advocacy Network. The program offers new and seasoned advocates the opportunity to improve their skills and understanding of the research system and scientific concepts. Each selected Scholar participates in preparatory conference calls, virtual classes (webinars), learning materials and mentoring so they can improve their skills and understanding of biomedical research. This preparation culminates with attendance at the American Society of Clinical Oncology Annual Meeting. Scholars then report back to their patient constituencies.
Dr. Alan Venook wins the 2016 Blue Faery Award
Dr. Alan Venook wins the 2016 Blue Faery Award for Excellence in Liver Cancer Research
As the leader of the gastrointestinal oncology clinical program and the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco, Dr. Alan Venook is a nationally recognized expert in colorectal and liver cancers. He has published more than 70 original articles, chapters or books dealing with gastrointestinal malignancies. Dr. Venook has chaired the Scientific Program for ASCO 2015 and the National Cancer Institute’s (NCI) Hepatobiliary Task Force. He is a member of NCI’s Gastrointestinal Cancer Steering Committee and currently chairs the Gastrointestinal Committee of the Alliance for Clinical Trials in Oncology, where he oversees an extensive clinical trial portfolio.